RedHill Biopharma, IntelGenx Announce European Marketing Approval For Rizaport

(RTTNews) - Israeli biopharmaceutical company RedHill Biopharma Ltd. (RDHL) together with Canadian drug delivery company IntelGenx Corp. (IGX.TO) Monday said the Federal Institute for Drugs and Medical Devices of Germany has granted marketing authorization for Rizaport 5mg and 10mg, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The approval is under European Decentralized Procedure or EDP. RedHill and IntelGenx intend to continue to work together to obtain national phase approvals in other European DCP territories.

Over 50 million people in Europe are estimated to be affected by migraines. Approximately 2 million Europeans are prone to migraine attacks every day1. The worldwide migraine market is expected to exceed $2 billion in sales in 2016.

RIZAPORT is a therapeutic alternative for patients suffering from dysphagia (difficulty swallowing), and patients who suffer from migraine-related nausea.